Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with Pre- or post-treatment triple combination cream

Dermatologic Surgery

Volumn 36, Issue 6, 2010, Pages 909-918

  Jeong, Se Yeong ^a   Shin, Jae Bin ^a   Yeo, Un Cheol ^b   Kim, Won Serk ^c   Kim, Il Hwan ^a  

^a Korea University College of Medicine   (South Korea)

^b S and U Clinic   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; FLUOCINOLONE ACETONIDE PLUS HYDROQUINONE PLUS TRETINOIN; TRI LUMA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHLOASMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ERYTHEMA; FEMALE; HUMAN; HYPOPIGMENTATION; LEUKODERMA; MALE; MELASMA AREA AND SEVERITY INDEX; NEODYMIUM LASER; PAIN; PRIORITY JOURNAL; SCORING SYSTEM; SELF EVALUATION; SKIN IRRITATION; SPECTROPHOTOMETRY; TOPICAL TRIPLE COMBINATION THERAPY; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADULT; ANTIOXIDANTS; COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; HYDROQUINONES; KERATOLYTIC AGENTS; LASERS, SOLID-STATE; MALE; MELANOSIS; MIDDLE AGED; TREATMENT OUTCOME; TRETINOIN;

EID: 77952961823     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2010.01523.x     Document Type: Article

References (28)

1. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin 2000 18 : 91 8.
2. Gupta AK, Gover MD, Nouri K, et al. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 2006 55 : 1048 1065.
3. Ando H, Kondoh H, Ichihashi M, et al. Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase. J Invest Dermatol 2007 127 : 751 761.
4. Kang WH, Yoon KH, Lee ES, et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol 2002 146 : 228 237.
5. Vazquez M, Sanchez JL. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. Cutis 1983 32 : 92 6.
6. Torok HM. A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream. Am J Clin Dermatol 2006 7 : 223 230.
7. Torok HM, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis 2005 75 : 57 62.
8. Cestari TF, Hassun K, Sittart A. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol 2007 6 : 36 9.
9. Jeong SY, Chang SE, Park HN, et al. New melasma treatment by collimated low fluence Q-switched Nd:YAG Laser. Korean J Dermatol 2008 46 : 1163 1170.
10. Tse Y, Levine VJ, McClain SA, et al. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium: yttrium-aluminum-garnet laser. J Dermatol Surg Oncol 1994 20 : 795 800.
11. Polnikorn N. Treatment of refractory dermal melasma with the Medlite C6 Q-switched Nd:YAG laser: two case reports. J Cosmet Laser Ther 2008 10 : 167 173.
12. Hurley ME, Guevara IL, Gonzales RM, et al. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol 2002 138 : 1578 1582.
13. Erbil H, Sezer E, Tastan B, et al. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. J Dermatol 2007 34 : 25 30.
14. Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol 1994 20 : 592 597.
15. Kim MJ, Kim JS, Cho SB. Punctate leucoderma after melasma treatment using 1,064-nm Q-switched Nd:YAG laser with low pulse energy. J Eur Acad Dermatol Venereol 2009 23 : 960 962.
16. Haddad AL, Matos LF, Brunstein F, et al. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs placebo in the treatment of melasma. Int J Dermatol 2003 42 : 153 156.
17. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975 111 : 40 8.
18. Astaneh R, Farboud E, Nazemi MJ. 4% hydroquinone versus 4% hydroquinone, 0.05% dexamethasone and 0.05% tretinoin in the treatment of melasma: a comparative study. Int J Dermatol 2005 44 : 599 601.
19. Gano SE, Garcia RL. Topical tretinoin, hydroquinone, and betamethasone valerate in the therapy of melasma. Cutis 1979 23 : 239 241.
20. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003 72 : 67 72.
21. Chan R, Park KC, Lee MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol 2008 159 : 697 703.
22. Grekin RC, Shelton RM, Geisse JK, et al. 510-nm pigmented lesion dye laser. Its characteristics and clinical uses. J Dermatol Surg Oncol 1993 19 : 380 387.
23. Anderson RR, Parrish JA. Selective phothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983 220 : 524 527.
24. Rokhsar CK, Fitzpatrick RE. The treatment of melasma with fractional photothermolysis: a pilot study. Dermatol Surg 2005 31 : 1645 1650.
25. Katsambas A, Antoniou C. Melasma: classification and treatment. J Eur Acad Dermatol Venereol 1995 4 : 217 275.
26. Gilchrest BA, Fitzpatrick TB, Anderson RR, et al. Localization of melanin pigmentation in the skin with Wood's lamp. Br J Dermatol 1977 96 : 245 248.
27. Negishi K, Kushikata N, Tezuka Y, et al. Study of the incidence and nature of "very subtle epidermal melasma" in relation to intense pulsed light treatment. Dermatol Surg 2004 30 : 881 886.
28. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol 2005 27 : 96 101.